Tiragolumab

GSK and iTeos presented belrestotug + Jemperli data at ESMO 2024, showing doubled ORR in NSCLC, but lacking survival insights. Belrestotug 400mg is the RP3D for Phase III trial vs. Keytruda. TIGIT inhibitors face competition from Roche, Arcus/Gilead, and AstraZeneca, with market potential of $871m by 2030.

GSK and iTeos' anti-TIGIT antibody belrestotug, combined with GSK's PD-1 inhibitor Jemperli, showed higher objective response rates in PD-L1-positive NSCLC patients in the GALAXIES Lung-02 study, though with higher discontinuation rates and treatment-related deaths. The 400mg dose is moving to phase 3 trials.

iTeos Therapeutics' mid-stage trial results show its drug, when combined with GSK's immunotherapy, shrank lung tumors in twice as many patients compared to GSK's therapy alone. The trial raised safety concerns due to three treatment-related deaths from immune-related inflammation. Despite previous failures of TIGIT-targeting drugs, iTeos' data could rekindle interest in the target, with further data expected to clarify the combination's impact on survival and disease progression.

The FDA approved Roche's subcutaneous formulation of Tecentriq, branded as Tecentriq Hybreza, making it the first SC anti-PD-(L)1 cancer immunotherapy in the U.S. The SC option reduces treatment time to about 7 minutes compared to 30-60 minutes for IV infusion and is available for all Tecentriq indications.